We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

Sanofi completes acquisition of Blueprint Medicines. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialized medicine ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion).

Sanofi SA is to acquire Blueprint Medicines Inc. in a $9.5 billion deal that will give the French pharma ownership of a marketed rare disease immunotherapy heading toward blockbuster status, a ...

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the ...

Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising ...